While EGFR mutations were detected in 51 tissue samples from 80 patients with stage III or IV lung adenocarcinoma, they showed concordant results in 33 (65.0%) of the liquid biopsy samples taken from these cases (16). This evidence concerns the gene EGFR and lung adenocarcinoma.